tiprankstipranks
Advertisement
Advertisement

INMB Stock Latest News

Strengthening XPro1595 Data and De-Risked Registrational Path Support Buy Rating on INmune Bio with Unchanged $8 Price Target
RatingsStrengthening XPro1595 Data and De-Risked Registrational Path Support Buy Rating on INmune Bio with Unchanged $8 Price Target
2d ago
INMB
INmune Bio Executes Warrant Inducement and Extension Agreement
PremiumCompany Announcements
INmune Bio Executes Warrant Inducement and Extension Agreement
12d ago
8K
INMB
INmune Bio advances CORDStrom platform patent application in the U.S.
PremiumThe Fly
INmune Bio advances CORDStrom platform patent application in the U.S.
12d ago
INMB
INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan
PremiumThe Fly
INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan
18d ago
INMB
INmune Bio Advances Ebstrocel Toward UK Conditional Approval
PremiumCompany Announcements
INmune Bio Advances Ebstrocel Toward UK Conditional Approval
19d ago
8K
INMB
INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting
PremiumThe FlyINmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting
19d ago
INMB
Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan
Premium
Company Announcements
Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan
25d ago
8K
INMB
Maintained Buy on INmune Bio as Compelling Phase 2 Alzheimer’s Data Support XPro1595; $8 Price Target Reiterated
Premium
Ratings
Maintained Buy on INmune Bio as Compelling Phase 2 Alzheimer’s Data Support XPro1595; $8 Price Target Reiterated
1M ago
INMB
INmune Bio reports positive Phase 2 MRI results
PremiumCompany Announcements
INmune Bio reports positive Phase 2 MRI results
1M ago
8K
INMB
INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial
PremiumThe Fly
INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial
1M ago
INMB
Inmune Bio Charts Regulatory Path Amid Cash Constraints
PremiumCompany Announcements
Inmune Bio Charts Regulatory Path Amid Cash Constraints
2M ago
INMB
INmune Bio publishes MINDFuL trial results in NPJ Dementia
PremiumThe Fly
INmune Bio publishes MINDFuL trial results in NPJ Dementia
2M ago
INMB
INmune Bio Receives FDA Fast Track for XPro
PremiumCompany AnnouncementsINmune Bio Receives FDA Fast Track for XPro
2M ago
8K
INMB
INmune Bio receives fast track designation from FDA for XPro
Premium
The Fly
INmune Bio receives fast track designation from FDA for XPro
2M ago
INMB
Inmune Bio Advances CORDStrom Amid Funding Pressures
Premium
Company Announcements
Inmune Bio Advances CORDStrom Amid Funding Pressures
2M ago
INMB
INmune Bio Expands Cord Tissue License for CORDStrom Platform
PremiumCompany Announcements
INmune Bio Expands Cord Tissue License for CORDStrom Platform
2M ago
8K
INMB
INmune Bio announces new preclinical data for INB03
PremiumThe Fly
INmune Bio announces new preclinical data for INB03
3M ago
INMB
Inmune Bio Earnings Call Balances Progress and Risk
PremiumCompany Announcements
Inmune Bio Earnings Call Balances Progress and Risk
3M ago
INMB
INMB Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
INMB Upcoming Earnings Report: What to Expect?
4M ago
INMB
INmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s
PremiumThe FlyINmune Bio’s MINDFuL trial presented as succesful example in Alzheimer’s
4M ago
INMB
INmune Bio upgraded to Buy from Neutral at Lucid Capital
Premium
The Fly
INmune Bio upgraded to Buy from Neutral at Lucid Capital
4M ago
INMB
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
Premium
Company Announcements
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
5M ago
INMB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >